Clinical trials targeting lung cancer with active immunotherapy: The scope of vaccines

Luis E. Raez, Edgardo S. Santos, Raja Mudad, Eckhard R. Podack

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Successful active immunotherapy is expected to be specific and nontoxic. Until now, the success of immunotherapy in cancer has been sporadic and unpredictable. This has been attributable in part to the lack of a full understanding of the mechanistic underpinnings of immune regulation. Furthermore, the lack of systematic success of immunotherapy, as argued in this review, stems from failing to effectively target tumors such as non-small cell lung cancer. In this review, the rationale and design for induction of immunity to non-small cell lung cancer and clinical trials of the most important lung cancer vaccines in development are discussed.

Original languageEnglish
Pages (from-to)635-644
Number of pages10
JournalExpert Review of Anticancer Therapy
Volume5
Issue number4
DOIs
StatePublished - Aug 1 2005
Externally publishedYes

Fingerprint

Active Immunotherapy
Non-Small Cell Lung Carcinoma
Immunotherapy
Lung Neoplasms
Vaccines
Clinical Trials
Cancer Vaccines
Immunity
Neoplasms

Keywords

  • B7.1
  • BEC
  • CD80
  • Fucosyl
  • GM-1-keyhole limpet hemocyanin
  • GVAX
  • Immunotherapy
  • MUC1
  • Non-small cell lung cancer
  • Small cell lung cancer
  • Vaccine

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

Clinical trials targeting lung cancer with active immunotherapy : The scope of vaccines. / Raez, Luis E.; Santos, Edgardo S.; Mudad, Raja; Podack, Eckhard R.

In: Expert Review of Anticancer Therapy, Vol. 5, No. 4, 01.08.2005, p. 635-644.

Research output: Contribution to journalArticle

Raez, Luis E. ; Santos, Edgardo S. ; Mudad, Raja ; Podack, Eckhard R. / Clinical trials targeting lung cancer with active immunotherapy : The scope of vaccines. In: Expert Review of Anticancer Therapy. 2005 ; Vol. 5, No. 4. pp. 635-644.
@article{dbd54dc4cdda41de9c6356b0c9eb8585,
title = "Clinical trials targeting lung cancer with active immunotherapy: The scope of vaccines",
abstract = "Successful active immunotherapy is expected to be specific and nontoxic. Until now, the success of immunotherapy in cancer has been sporadic and unpredictable. This has been attributable in part to the lack of a full understanding of the mechanistic underpinnings of immune regulation. Furthermore, the lack of systematic success of immunotherapy, as argued in this review, stems from failing to effectively target tumors such as non-small cell lung cancer. In this review, the rationale and design for induction of immunity to non-small cell lung cancer and clinical trials of the most important lung cancer vaccines in development are discussed.",
keywords = "B7.1, BEC, CD80, Fucosyl, GM-1-keyhole limpet hemocyanin, GVAX, Immunotherapy, MUC1, Non-small cell lung cancer, Small cell lung cancer, Vaccine",
author = "Raez, {Luis E.} and Santos, {Edgardo S.} and Raja Mudad and Podack, {Eckhard R.}",
year = "2005",
month = "8",
day = "1",
doi = "10.1586/14737140.5.4.635",
language = "English",
volume = "5",
pages = "635--644",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Clinical trials targeting lung cancer with active immunotherapy

T2 - The scope of vaccines

AU - Raez, Luis E.

AU - Santos, Edgardo S.

AU - Mudad, Raja

AU - Podack, Eckhard R.

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Successful active immunotherapy is expected to be specific and nontoxic. Until now, the success of immunotherapy in cancer has been sporadic and unpredictable. This has been attributable in part to the lack of a full understanding of the mechanistic underpinnings of immune regulation. Furthermore, the lack of systematic success of immunotherapy, as argued in this review, stems from failing to effectively target tumors such as non-small cell lung cancer. In this review, the rationale and design for induction of immunity to non-small cell lung cancer and clinical trials of the most important lung cancer vaccines in development are discussed.

AB - Successful active immunotherapy is expected to be specific and nontoxic. Until now, the success of immunotherapy in cancer has been sporadic and unpredictable. This has been attributable in part to the lack of a full understanding of the mechanistic underpinnings of immune regulation. Furthermore, the lack of systematic success of immunotherapy, as argued in this review, stems from failing to effectively target tumors such as non-small cell lung cancer. In this review, the rationale and design for induction of immunity to non-small cell lung cancer and clinical trials of the most important lung cancer vaccines in development are discussed.

KW - B7.1

KW - BEC

KW - CD80

KW - Fucosyl

KW - GM-1-keyhole limpet hemocyanin

KW - GVAX

KW - Immunotherapy

KW - MUC1

KW - Non-small cell lung cancer

KW - Small cell lung cancer

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=24044535726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044535726&partnerID=8YFLogxK

U2 - 10.1586/14737140.5.4.635

DO - 10.1586/14737140.5.4.635

M3 - Article

C2 - 16111464

AN - SCOPUS:24044535726

VL - 5

SP - 635

EP - 644

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 4

ER -